MedTrace Logo

Integrating Hepatitis C Screening With Dried Blood Spot Testing Into Colorectal Cancer Screening

NCT04037046 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 609

Last updated 2021-04-30

No results posted yet for this study

Summary

The main purpose of the study is to compare the acceptance and viability of three strategies aimed to screen hepatitis C virus (HCV) infection in a birth cohort by: a) invitation letter offering HCV screening with dried blood spot (DBS) testing at the primary care center, b) invitation letter offering both HCV and colorectal cancer (CCR) screening with faecal occult test (FOT) at the primary care center, and c) invitation letter offering self-collected screening at home for HCV and CCR.

Conditions

  • Hepatitis C Virus Infection

Interventions

BEHAVIORAL

Screening HCV attached onto CCR screening

Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner

BEHAVIORAL

Screening HCV attached onto CCR screening by self-testing

Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT

BEHAVIORAL

Screening HCV at primary care center

DBS for HCV screening at primary care center

Sponsors & Collaborators

  • University of La Laguna

    lead OTHER

Principal Investigators

  • Manuel Hernandez-Guerra, MD · MD

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2019-11-01
Completion
2019-11-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04037046 on ClinicalTrials.gov